Abshagen U, Betzien G, Endele R, Kaufmann B
Eur J Clin Pharmacol. 1981;20(4):269-75. doi: 10.1007/BF00618777.
The pharmacokinetics of isosorbide-5-mononitrate (IS-5-MN) has been studied in two groups of healthy volunteers after oral (n = 20) and intravenous (n = 11) administration of 20 mg, which had previously been proved to be as effective as 20 mg sustained-release isosorbide dinitrate (ISDN). IS-5-MN in serum was measured by gas chromatography using capillary columns. The kinetic calculations were carried out with a newly developed model, which assumes a virtual volume of distribution dependent on time. IS-5-MN is rapidly (invasion half-life 4.1 min) and completely absorbed from the gastro-intestinal tract without any first pass metabolism. The maximum concentration of 480 micrograms/l was reached 1.2 h after oral administration of 20 mg. The substance was distributed throughout the total body water (distribution coefficient: 0.62), and was eliminated with a terminal t1/2 of 4.1 and 4.6 h after oral and intravenous administration, respectively. Total body clearance was 115ml/min. Thus, IS-5-MN is unlike ISDN with respect to the absence of first-pass metabolism and an 8-times longer half-life. The consequences for therapy are discussed.
在两组健康志愿者中研究了单硝酸异山梨酯(IS - 5 - MN)的药代动力学,这两组志愿者分别口服(n = 20)和静脉注射(n = 11)20 mg该药物,此前已证明20 mg单硝酸异山梨酯与20 mg缓释硝酸异山梨酯(ISDN)疗效相当。血清中的IS - 5 - MN采用毛细管柱气相色谱法测定。动力学计算采用新开发的模型进行,该模型假定分布虚拟体积随时间变化。IS - 5 - MN从胃肠道迅速吸收(侵入半衰期4.1分钟)且完全吸收,无任何首过代谢。口服20 mg后1.2小时达到最大浓度480微克/升。该物质分布于全身水分中(分布系数:0.62),口服和静脉注射后消除的终末t1/2分别为4.1小时和4.6小时。全身清除率为115毫升/分钟。因此,IS - 5 - MN与ISDN不同,不存在首过代谢且半衰期长8倍。文中讨论了其对治疗的影响。